Subclinical hypothyroidism: Should we treat?

Area of Science:

• Endocrinology
• Thyroidology
• Internal Medicine

Background:

• Subclinical hypothyroidism (SCH) is defined by elevated serum thyroid-stimulating hormone (TSH) with normal serum free thyroxine (FT4).
• It is a prevalent condition, particularly in women over 55, with autoimmune thyroid disease being the most frequent cause.
• Approximately 2.5% of SCH patients progress to overt hypothyroidism annually, with higher rates in those with thyroid autoantibodies and elevated TSH levels.

Purpose of the Study:

• To review the definition, prevalence, causes, natural course, and clinical implications of subclinical hypothyroidism.
• To discuss the evidence regarding levothyroxine treatment for symptoms and cardiovascular risks associated with SCH.
• To highlight the factors influencing the decision-making process for treating subclinical hypothyroidism.

Main Methods:

• Literature review and synthesis of current evidence on subclinical hypothyroidism.
• Analysis of progression rates, spontaneous normalization, and risk factors.
• Evaluation of the efficacy of levothyroxine treatment for symptoms and cardiovascular outcomes.

Main Results:

• Up to 40% of subclinical hypothyroidism cases normalize spontaneously.
• Levothyroxine's efficacy in ameliorating symptoms in SCH patients is weakly supported by evidence.
• SCH in patients under 65 is linked to increased cardiovascular disease risk, particularly with TSH levels ≥10.0 mU/L.

Conclusions:

• Treatment decisions for subclinical hypothyroidism should be individualized, considering age, symptoms, thyroid antibodies, and cardiovascular risk factors.
• While levothyroxine may reduce coronary heart disease risk in younger patients, robust evidence from randomized controlled trials is lacking.
• Careful consideration of patient-specific factors is crucial for managing subclinical hypothyroidism.